Infusion coding can be complex, challenging coders and compliance professionals alike. There is an important and confusing newer service for 2023 that requires comprehensive knowledge in order to report and bill accurately. Our insight aims to breakdown the obstacles while exploring some of the intricacies of cellular and gene therapies, with a specific focus on chimeric antigen receptor therapy (CAR-T), which uses genetically modified T cells, to clarify reporting in this area. With some of this fundamental knowledge, we can help calm the confusion and shape your success with this service in 2023 and beyond.
First, it is important to note that Medicare pays for the administration of CAR T-cells in the hospital outpatient setting separately under CPT® code 0540T with revenue Code 0874. Code 0540T continues to be assigned to status indicator “S” (Procedure or Service, Not Discounted When Multiple) under the OPPS.
| 0540T | Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous
Revenue Code: 874 |
So, what does CAR-T encompass? The treatments involve the following elements:
Codes 0537T, 0538T, 0539T, 0540T establish the various steps required to collect, prepare, transport, receive, and administer genetically modified T cells. Note that the collection and handling code (0537T) may be reported only once per day, regardless of the number of collections or quantity of cells collected. Similarly, the administration code (0540T) may only be reported once per day, regardless of the number of units administered. Coders should be cautious and understand that the development of genetically modified cells is not reported with this family of codes.
The specialized services outlined in codes 0537T, 0538T, and 0539T are not conducted within hospital premises. Instead, these essential steps in cellular and gene therapies are carried out by dedicated specialty labs or contracted manufacturers. These experts play a crucial role, ensuring the highest standards of care and precision are performed.
The CAR-T therapy journey commences with the collection of cells from the patient through peripheral blood leukocyte cell harvesting. These cells, essential for the therapy’s success, are carefully obtained to ensure their optimal quality. After collection, the cells are prepared for processing or shipping to a specialized manufacturing or cell processing facility, if required. This preparation may involve cryopreservation or other techniques to maintain the cells’ integrity during transportation.
The procedure to administer CAR-T cells includes the following components:
Coders may be wondering how the term “care” on the same date of service that is not directly related to the service of administration of the CAR-T cells is defined and how it may be reported. This type of care is essentially defined as care provided after the administration is complete, care for the patient’s underlying condition, or for other medical problems. Under these circumstances, this service may be separately reported using the appropriate evaluation and management code with modifier 25. However, coders should make special note that management of uncomplicated adverse events (e.g., nausea, urticaria) during the infusion is not reported separately.
Separate reporting is a common area of confusion for many coders time and time again. Like with other services, CAR-T has some critical points worth noting in this area. First, the fluid used to administer the cells and other infusions for incidental hydration (e.g., 96360, 96361) are not reported separately. Similarly, infusion(s) of any supportive medication(s) (e.g., steroids) concurrently with the CAR-T cell administration are not reported separately. However, one key exception is hydration or administration of medications (e.g., antibiotics, opioids) unrelated to the CAR-T administration. When these are administered, they may be reported separately with modifier 59. It is also common for lymphodepleting (LD) chemotherapy (e.g., Bendamustine, Fludarabine and Cyclophosphamide) to be added to the patient’s treatment plan. This form of chemotherapy is usually performed days before infusion of the CAR-T cells. Our experts note that chemotherapy drugs administered may be reported with applicable chemotherapy drug administration codes on the date they were performed.
The physician or other qualified health care professional evaluates the patient immediately before the autologous CAR-T infusion and monitors multiple physiologic parameters, including frequent monitoring of vital signs and clinical status. The physician or other qualified health care professional, nurse, and cell-processing technologist hold multiple responsibilities in ensuring the success of the process These include reviewing:
During the infusion process, the physician or qualified healthcare professional must be present for 15 to 30 minutes (possibly longer depending on the infusion rate). Their presence ensures the proper initiation of the product infusion and allows for immediate response in managing any potential toxicities or complications that may arise during or immediately after the infusion.
To ensure accurate billing and coding for CAR-T therapy, it’s essential to refer to CMS MLN Matters Number: MM11216, which provides valuable guidance on billing scenarios specific to various healthcare settings. Particularly in the hospital outpatient setting, it’s important to use the appropriate codes for reporting. CPT code 0540T should be used to report the administration of the CAR-T drug, while HCPCS Q-codes, specifically Q2041 or Q2042, should be utilized to report the drug/biological.
It’s worth noting that the procedures described by CPT codes 0537T (collection/handling), 0538T (preparation for transport), and 0539T (receipt and preparation) represent the various steps required to collect the cells and prepare the genetically modified T-cells, are not separately payable. However, these services may be reported as non-covered charges on the outpatient claim. This is noted in the CY 2019 OPPS/ASC final rule.
By focusing on accurate billing and proper reimbursement, healthcare professionals should stay updated on the latest coding guidelines and regulations. By following the appropriate coding practices and referencing official resources, you can ensure accurate documentation and streamline the billing process for CAR-T therapy and related services.
These are not all the necessary coding tips and rationale essential for CAR-T therapy and infusion therapy coding. As service volumes rebound and every dollar counts more than ever, it is imperative to make sure your CPT® coding is correct and compliant. Master more topics in our Coding Essentials for Infusion & Injection Therapy Services resource, fully equipped with expert-infused guidance tailored to your needs.
Information Source:
The Medicare Advantage (MA) program has grown significantly over the past two decades, becoming a popular alternative to traditional Medicare fee-for-service (FFS). As of 2023,
The Medicare and Medicaid provider auditing process is about to get a makeover in 2025. I am talking about artificial intelligence (AI), which may be
Please log in to your account to comment on this article.
Prepare your organization for the 2025 OPPS updates with expert insights from Tiffani Bouchard, CCS, CRCR, a Revenue Integrity Professional with over 30 years of experience. This webcast will address critical challenges in charge capture and coding, providing clarity on APC policies, C-APC packaging, exclusions, and payer-specific requirements. Attendees will learn actionable strategies to ensure compliance, optimize reimbursement, and mitigate risks of claim denials. Gain the knowledge needed to implement updates effectively, educate your team, and maintain seamless revenue cycle operations in the face of evolving OPPS complexities.
Join Beth Wolf, MD, CPC, CCDS, for an in-depth webcast on the FY2025 spinal fusion MS-DRG updates. Discover key changes in DRG classification, understand impacts on documentation and CMI, and learn strategies to ensure compliance.
Join Angela Comfort, DBA, MBA, RHIA, CDIP, CCS, CCS-P, as she presents effective strategies to strengthen collaboration between CDI, coding, and quality departments in acute care hospitals. Angela will also share guidance on implementing cross-departmental meetings, using shared KPIs, and engaging leadership to foster a culture of collaboration. Attendees will gain actionable tools to optimize documentation accuracy, elevate quality metrics, and drive a unified approach to healthcare goals, ultimately enhancing both patient outcomes and organizational performance.
Optimize your outpatient clinical documentation and gain comprehensive knowledge from foundational practices to advanced technologies, ensuring improved patient care and organizational and financial success. This webcast bundle provides a holistic approach to outpatient CDI, empowering you to implement best practices from the ground up and leverage advanced strategies for superior results. You will gain actionable insights to improve documentation quality, patient care, compliance, and financial outcomes.
The 2025 Medicare Physician Fee Schedule brings significant changes to payment rates, coverage, and coding for physician services, impacting practices nationwide. Join Stanley Nachimson, MS., as he provides a comprehensive guide to understanding these updates, offering actionable insights on new Medicare-covered services, revised coding rules, and payment policies effective January 1. Learn how to adapt your practices to maintain compliance, maximize reimbursement, and plan for revenue in 2025. Whether you’re a physician, coder, or financial staff member, this session equips you with the tools to navigate Medicare’s evolving requirements confidently and efficiently.
Dr. Ronald Hirsch provides critical details on the new Medicare Appeal Process for Status Changes for patients whose status changes during their hospital stay. He also delves into other scenarios of hospital patients receiving custodial care or medically unnecessary services where patient notifications may be needed along with the processes necessary to ensure compliance with state and federal guidance.
Healthcare organizations face complex regulatory requirements under the No Surprises Act and Price Transparency rules. These policies mandate extensive fee disclosures across settings, and confusion is widespread—many hospitals remain unaware they must post every contracted rate. Non-compliance could lead to costly penalties, financial loss, and legal risks. Join David M. Glaser Esq. as he shows you how to navigate these regulations effectively.
Protect your facility from unwanted audits! Join Becky Jacobsen, BSN, RN, MBS, CCS-P, CPC, CPEDC, CBCS, CEMC, and take a deep dive into both the CMS and AMA guidelines for reporting post operative pain blocks. You’ll learn how to determine if the nerve block is separately codable with real life examples for better understanding. Becky will also cover how to evaluate whether documentation supports medical necessity, offer recommendations for stronger documentation practices, and provide guidance on educating providers about documentation requirements. She’ll include a discussion of appropriate modifier and diagnosis coding assignment so that you can be confident that your billing of post operative pain blocks is fully supported and compliant.
Copyright © 2025 RACmonitor. Powered by MedLearn Media.
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24
